Industry

Explore the future of wellness with SynBalance at Vitafoods

Join SynBalance at Vitafoods Europe 2024, held at Palexpo, Switzerland from May 14th to May 16th.

Novo Nordisk Foundation, Wellcome, and Gates Foundation Forge Alliance to Tackle Microbiome Challenges

This unprecedented partnership signifies a concerted effort to address pressing microbiome-related challenges and advance health equity worldwide.

Nutrigenomics: from Biofarma an innovative approach to cardiometabolic diseases

Biofarma Group has consolidated its expertise in the formulation of dietary supplements aimed at cardiometabolic well-being.

New era in infant nutrition: Lallemand Health Solutions and DSM-Firmenich formulate synbiotic solutions

Isabelle Champié: “At Lallemand Health Solutions, we are committed to pushing the boundaries of probiotic research and development to create solutions that promote optimal health and well-being.

Flow cytometry: from Biofarma Group, a new approach for probiotic counting

A team of researchers have carried out a study on the search for bacterial probiotics, using a new method: flow cytometry

Advanced long-read sequencing services revolutionize microbiome analysis

Clinical Microbiomics sets a new standard in microbial research with unmatched data precision and resolution.

Sacco System unveils new biotech development site in Brisbane

Sacco System announces the grand opening of its development site in Australia.

Tailoring pet health: Nestlé’s new kit personalizes nutrition based on pet microbiome analysis

The new kit is part of the 'Petivity by Purina Petcare' ecosystem, which uses advanced tools to improve pet health and longevity through enhanced nutritional science.

Consumer behavior in probiotic consumption

MicrobiomePost carried out a research analysis in collaboration with Analytics Arts to find out more about the motivations and frequency of probiotic consumption and the level of consumer information.

MaaT Pharma demonstrates significant survival benefits with MaaT013 in Acute Graft-Versus-Host Disease

These findings underscore MaaT013's potential as a third-line treatment option, where traditional treatments often fall short.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top